Clinical Significance Of EIL4E Expression And The Correlation With CCND1, C-myc In AML Patients

Objective：To assay eukaryotic translation initiation factor (eIF4E) expression levelsand the relevance with cell cycle regulators as cyclin D1(CCND1) and c-myc levelsin bone marrow samples from acute myeloid leukemia (AML) patients of varioussubtype and various disease states as non-treatment, remission, non-remission/relapse.To investigate the clinical factors that impacts expression levels of eIF4E, CCND1and c-myc. To explore the availability of detecting eIF4E overexpression levels as amolecular biology marker to monitor AML progression.Methods：92bone marrow (BM) specimens collected from60patients diagnosed asAML by using MICM (morphology, immunology, cytogenetics and molecular)technique and typied in FAB classification.30BM specimens collected from30persons with or without non-neoplasma hematologic disease were control groupe.eIF4E, CCN D1and c-myc mRNA were measured by SYBRGreenI RT-PCR, settingβ2-Microglobulin as endogenous control. The relative quantification of geneexpression level was caculated by2-ΔCtmethod correlated with absolation genequantification using standard curvs. Statistics analysis software SPSS13.0was used tostudy expression levels difference of each detected target gene between AML groupesand controls, and to analyze the correlation of eIf4E exprssion level with cyclin D1,c-myc expression level and clinical parameters.Results：1. eIF4E mRNA level detected in non-treated AML and non-remission/relapse AML group was higher than remission group and control group. Thedifference is statistically significant (P<0.05). There is no statistical differencebetween the eIF4E level in group of non-treatment and relapse/non-remission(P=0.379). Although eIF4E expresses slightly higher in the remission than controlgroup, but there is no statistical significance (P=0.803). Compaeing eIF4E level inAML subtypes suggested that there was no statistical difference between subtype ofM4and M5(P=0.248) which was l higher than others (P<0.05).2. The expression level of CCND1in non-treated AML and non-remission/relapse AML is obviouslyhigher than remission AML and control group (P<0.05). There is no statisticalsignificant difference between non-treated and non-remission/relapse AML group(P=0.569), remission AML and control group (P=0.949). The comparison of CCND1level between AML subtypes shows no difference (P=0.176).3. The expression levelof c-myc in non-treated AML and non-remission/relapse AML group is obviouslyhigher than remission AML and control group (P<0.05). There is no statisticalsignificant difference between non-treated and non-remission/relapse AML (P=0.165),remission AML and control group (P=0.943). The comparison of c-myc level betweeneach AML subtypes shows no difference (P=0.720).4. The analysis suggests thateIF4E expression level correlate positively with CCND1(correlation coeficient:R=0.709, P=0.000) and c-myc (corelation coeficient: R=0.722, P=0.000).5. Multipleregression analysis suggests there is positive correlation of BM blast percentigewith eIF4E level (P=0.000), and no significan correlation with patients age, genderand hemoglobin concentration, platelet amount in blood.Conclusion：The study suggests eIF4E high expression detected in non-remissionAML patients, and higher in M4, M5than other AML subtype. The eIF4E expressionlevel positively correlates with blast cell percentage in bone marrow, leukocyteamount in peripherial blood and the expression level of cell cycle regulator CCND1and c-myc, no correlate with clinical parameters as age, gender, hemoglobin andplatelet amount.